Latanoprostene Bunod
Brand name: Vyzulta
Rank #284 of 500 drugs by total cost
$41.6M
Total Cost
92,705
Total Claims
$41.6M
Total Cost
2,181
Prescribers
$449
Cost per Claim
18,521
Beneficiaries
138,837
30-Day Fills
$19K
Avg Cost/Provider
43
Avg Claims/Provider
About Latanoprostene Bunod
Latanoprostene Bunod (sold as Vyzulta) was prescribed 92,705 times by 2,181 Medicare Part D providers in 2023, costing the program $41.6M. At $449 per claim, this is a moderately priced medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 281 | Hydrochlorothiazide (Hydrochlorothiazide) | $42.4M | 7,879,021 |
| 282 | Tadalafil (Tadalafil) | $42.3M | 91,082 |
| 283 | Topiramate (Topiramate) | $41.9M | 1,141,093 |
| 284 | Latanoprostene Bunod (Vyzulta) | $41.6M | 92,705 |
| 285 | Travoprost (Travoprost) | $41.5M | 178,599 |
| 286 | Alendronate Sodium (Alendronate Sodium) | $41.4M | 3,414,824 |
| 287 | Daptomycin (Daptomycin) | $41.2M | 41,245 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology